KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Other Non-Current Assets (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Other Non-Current Assets for 17 consecutive years, with $109.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets rose 5.19% to $109.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $109.0 million, a 5.19% increase, with the full-year FY2024 number at $101.9 million, up 7.38% from a year prior.
  • Other Non-Current Assets was $109.0 million for Q3 2025 at Bio-Rad Laboratories, up from $107.9 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $109.0 million in Q3 2025 to a low of $92.2 million in Q1 2021.
  • A 5-year average of $101.0 million and a median of $100.9 million in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: rose 29.48% in 2021, then dropped 9.21% in 2022.
  • Bio-Rad Laboratories' Other Non-Current Assets stood at $104.2 million in 2021, then decreased by 9.21% to $94.6 million in 2022, then rose by 0.32% to $94.9 million in 2023, then grew by 7.38% to $101.9 million in 2024, then increased by 6.97% to $109.0 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Other Non-Current Assets are $109.0 million (Q3 2025), $107.9 million (Q2 2025), and $101.9 million (Q4 2024).